Palvella Therapeutics Files 8-K

Ticker: PVLA · Form: 8-K · Filed: Dec 15, 2025 · CIK: 1583648

Palvella Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyPalvella Therapeutics, Inc. (PVLA)
Form Type8-K
Filed DateDec 15, 2025
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: 8-K, financial-statements, corporate-update

TL;DR

Palvella Therapeutics (formerly Pieris) filed an 8-K on 12/15/25 covering financials and other events.

AI Summary

On December 15, 2025, Palvella Therapeutics, Inc. (formerly Pieris Pharmaceuticals, Inc.) filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with a Regulation FD disclosure and other events. The company, incorporated in Nevada, is involved in the Pharmaceutical Preparations industry.

Why It Matters

This 8-K filing provides updated information and disclosures for Palvella Therapeutics, Inc., which is crucial for investors to stay informed about the company's current status and any material events.

Risk Assessment

Risk Level: low — This filing is a routine 8-K reporting financial statements and other events, not indicating any immediate significant financial distress or major corporate action.

Key Players & Entities

  • PALVELLA THERAPEUTICS, INC. (company) — Registrant
  • Pieris Pharmaceuticals, Inc. (company) — Former company name
  • December 15, 2025 (date) — Date of earliest event reported
  • Nevada (jurisdiction) — State of incorporation
  • 300784346 (identifier) — IRS Employer Identification No.

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report financial statements and exhibits, along with a Regulation FD disclosure and other events, as of December 15, 2025.

What was Palvella Therapeutics, Inc. formerly known as?

Palvella Therapeutics, Inc. was formerly known as Pieris Pharmaceuticals, Inc.

In which state is Palvella Therapeutics, Inc. incorporated?

Palvella Therapeutics, Inc. is incorporated in Nevada.

What is the IRS Employer Identification Number for Palvella Therapeutics, Inc.?

The IRS Employer Identification Number for Palvella Therapeutics, Inc. is 300784346.

What is the business address of Palvella Therapeutics, Inc.?

The business address of Palvella Therapeutics, Inc. is 353 W. Lancaster Avenue, Suite 200, Wayne, PA 19087.

Filing Stats: 623 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2025-12-15 06:05:43

Key Financial Figures

  • $0.001 — ge on which registered Common stock, $0.001 par value per share PVLA The Nasdaq

Filing Documents

01

Item 7.01 Regulation FD Disclosure. On December 15, 2025, Palvella Therapeutics, Inc. (the " Company ") will host a conference call with investors at 8:30 a.m. Eastern Time, to present the topline results from the Company's Phase 2 TOIVA study of QTORIN 3.9% rapamycin anhydrous gel for the treatment of cutaneous venous malformations. The live event and accompanying slides can be accessed by visiting https://edge.media-server.com/mmc/p/cag4c7en/ . A copy of the investor presentation is furnished herewith as Exhibit 99.1, and incorporated herein by reference. The information furnished pursuant to Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

01

Item 8.01 Other Events. On December 15, 2025, the Company issued a press release announcing positive topline results from the Company's ongoing Phase 2 TOIVA study of QTORIN 3.9% rapamycin anhydrous gel for the treatment of cutaneous venous malformations. A copy of the press release is filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Document 99.1 Corporate Presentation on Phase 2 TOIVA Study of QTORIN dated December 15, 2025* 99.2 Press Release issued by Palvella Therapeutics, Inc. on December 15, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) *Furnished herewith

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PALVELLA THERAPEUTICS, INC. Date: December 15, 2025 By: /s/ Matthew Korenberg Matthew Korenberg Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.